Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea

Figure 2 The design and conduct of the SURMOUNT-obstructive sleep apnoea study. There were two parts of the study - part 1 was done on patients without background continuous positive airway pressure therapy while part 2 enrolled patients on background continuous positive airway pressure therapy. Tirzepatide was administered as once weekly injections in doses of 10 mg or 15 mg. AHI: Apnoea hypopnea index; CPAP: Continuous positive airway pressure; OSA: Obstructive sleep apnoea; TRP: Tirzepatide; PLB: Placebo.